Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:32am, Thursday, 12'th Jan 2023
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Health Care Stocks Outperform Again In 2023?
06:09pm, Wednesday, 11'th Jan 2023
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
Eli Lilly Had a Strong Year in 2022. It's Expecting an Even Better 2023.
03:15pm, Wednesday, 11'th Jan 2023 The Motley Fool
The company has multiple growth catalysts on the horizon that could propel the stock this year and beyond.
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
02:38pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
Eli Lilly Stock Could Reclaim Former Highs
01:04pm, Wednesday, 11'th Jan 2023
According to BMO, near-term hurdles such as competition for key drugs and patent expiries won't derail the long-term revenue and earnings growth of Eli Lilly And Co (NYSE:LLY).
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
11:20am, Wednesday, 11'th Jan 2023 Zacks Investment Research
Sector ETF report for IYH
Eli Lilly Had a Strong Year in 2022. It's Expecting an Even Better 2023.
10:15am, Wednesday, 11'th Jan 2023
The company has multiple growth catalysts on the horizon that could propel the stock this year and beyond.
Eli Lilly and Company (LLY) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
09:31pm, Tuesday, 10'th Jan 2023
Eli Lilly and Company (NYSE:LLY ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 6:45 PM ET Company Participants Anat Ashkenazi - Chief Financial Officer Daniel Skovronsky - Chief Scie
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day
01:27pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Eli Lilly (LLY)
11:20am, Tuesday, 10'th Jan 2023 Zacks Investment Research
Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth
Is Alexandria Real Estate Equity a Buy?
10:00am, Tuesday, 10'th Jan 2023 The Motley Fool
It's a great stock, but investors dislike the sector.
Bear of the Day: Eli Lilly (LLY)
07:32am, Tuesday, 10'th Jan 2023
Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth
Ranking The Top 10 Pharmaceuticals By Pipeline
11:44pm, Monday, 09'th Jan 2023
The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
03:04pm, Monday, 09'th Jan 2023 Zacks Investment Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
General Motors And These 2 Healthcare Majors On CNBC's 'Final Trades'
01:17pm, Monday, 09'th Jan 2023 Benzinga
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Pfizer Inc. (NYSE: PFE), saying that it offers "growth at a reasonable price."
Benzinga's analyst
